TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) (“Field Trip” or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022.


Previous articlePsychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley Opine on Psychedelics; COMPASS Rallies
Next articleBuried Treasure: How Does Psilocybin Reduce Compulsivity?